News Kineta, Inc.

Equities

KA

US49461C1027

Delayed Nasdaq Other stock markets 09:36:52 17/05/2024 pm IST			5-day change	1st Jan Change
0.4899 ^USD	+0.60%		-12.22%	-86.50%

08/04	Kineta, Inc. Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 Vista-101 Clinical Trial	CI
21/03	Earnings Flash (KA) KINETA Posts 2023 Revenue $5.4M	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Kineta Reports First Quarter 2024 Financial Results and Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial and Corporate Activities	16/05	AQ
Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial	09/04	AQ
Kineta, Inc. Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 Vista-101 Clinical Trial	09/04	CI
Earnings Flash (KA) KINETA Posts 2023 Revenue $5.4M	22/03	MT
Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update	22/03	AQ
KVA12123 Clears Additional Cohorts in Monotherapy and in Combination Therapy Arms in the Phase 1/2 VISTA-101 Clinical Trial; Initial Clinical Response Data Reported	12/03	AQ
Kineta, Inc. Announces an Update on Its Ongoing Vista-101 Phase 1/2 Clinical Trial Evaluating Kva12123	12/03	CI
Top Midday Decliners	01/03	MT
Kineta Announces Restructuring and Exploration of Strategic Alternatives	29/02	AQ
Kineta, Inc. Terminates Employment of Pauline Kenny as General Counsel and Secretary	29/02	CI
Kineta, Inc. Terminates Employment of Shawn Iadonato as CEO	29/02	CI
Kineta, Inc. Announces Restructuring and Workforce Reduction	29/02	CI
Kineta Announces Exploration of Strategic Alternatives	29/02	CI
Kineta to Present New Preclinical Data on its Anti-VISTA Antibody KVA12123 in Acute Myeloid Leukemia at the AACR Blood Cancer Discovery Symposium	22/02	AQ
Kineta to Present at Upcoming Investor Conferences	14/02	AQ
Kineta to Participate in H.C. Wainwright Virtual @Home Fireside Chat Series	07/02	AQ
Kineta Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors	17/01	AQ
Kineta, Inc. Announces Update on Ongoing Vista-101 Phase 1/2 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Tumor Activity	17/01	CI
Kineta to Participate in the 13th Annual LifeSci Partners Corporate Access Event	04/01	AQ
Kineta Publishes Preclinical Data Demonstrating the Potential of Anti-VISTA Antibody KVA12123 as an Immunomodulatory Therapy for Cancer	13/12	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Kineta, Inc.

Equities

KA

US49461C1027

Summary

Filters